Results 121 to 130 of about 48,845 (222)

Efficacy and Safety of Benmelstobart Plus Anlotinib in Advanced Endometrial Cancer: Results of a Multi‐Cohort, Phase II Study (ETER200)

open access: yesMedComm, Volume 7, Issue 11, November 2026.
The multi‐cohort, Phase II ETER200 study evaluated benmelstobart plus anlotinib or either agent alone in previously treated metastatic or recurrent endometrial cancer across molecular subtypes. In non–MSI‐H/pMMR tumors, benmelstobart plus anlotinib demonstrated durable antitumor activity without unexpected safety signals.
Shanhui Liang   +40 more
wiley   +1 more source

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib

open access: yesFrontiers in Pharmacology
BackgroundSunitinib is approved for the treatment of metastatic renal cell carcinoma (mRCC), imatinib-resistant gastrointestinal stromal tumors (GIST), and advanced pancreatic neuroendocrine tumors (PNET).
Xusheng Zhang   +6 more
doaj   +1 more source

Severe exacerbation of Crohn's disease during sunitinib treatment

open access: yes, 2014
Contains fulltext : 133887pub.pdf (Publisher’s version ) (Open Access)Sunitinib is a multiple tyrosine kinase inhibitor of the vascular endothelial growth factor and platelet-derived growth factor pathway and inhibits angiogenesis, cell
Nagtegaal, I.D.   +6 more
core   +1 more source

Efficacy and Safety of Lucitanib in Advanced Thymic Carcinoma: A Randomized Phase II Trial

open access: yesMedComm, Volume 7, Issue 11, November 2026.
In this randomized phase II trial, 68 patients with advanced thymic carcinoma after chemotherapy received lucitanib (n = 46) or placebo (n = 22). Median PFS was 5.8 versus 3.7 months by IRC (HR: 0.60; p = 0.105) and 6.6 versus 1.9 months by investigators (HR: 0.53; p = 0.031). Hypertension was the most common grade 3 TRAE (50%).
Wentao Fang   +21 more
wiley   +1 more source

In vivo characterization of sunitinib eluting beads

open access: yes, 2012
Purpose: To study the pharmacokinetics and potential toxicity of sunitinib eluting beads in an animal modelMaterials: Healthy New-Zealand white rabbits were used.
Jordan, O.   +6 more
core  

Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance

open access: yes, 2011
Purpose: Resistance to antiangiogenic tyrosine kinase inhibitors such as sunitinib is an important clinical problem, but its underlying mechanisms are largely unknown.
Mariette Labots   +14 more
core   +1 more source

OTUD1 Prevents Immunosuppression via Promoting Lysosomal‐Associated Degradation of PD‐L1

open access: yesMedComm, Volume 7, Issue 11, November 2026.
OTUD1 interacts with AKT and decreases AKT‐mTOR pathway activity, facilitating the translocation of TFEB to the nucleus, thereby triggering autophagy‐dependent degradation of PD‐L1 in lysosomes. . ABSTRACT Upregulation of PD‐L1 on tumor cells is a pivotal aspect of immune evasion, leading to treatment resistance, tumor recurrence, and metastasis ...
Yang Hao   +10 more
wiley   +1 more source

Management of Sunitinib-Associated Adverse Events [PDF]

open access: yes, 2012
Patients diagnosed with metastatic renal cell carcinoma (mRCC) are currently treated with oral tyrosine kinase inhibitors (TKIs). Sunitinib malate (Sutent R Pfizer INC) is an oral multitargeted TKI and is the mainstay of therapy for mRCC patients in ...
神田, 英輝   +4 more
core  

Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer

open access: yes, 2014
Item does not contain fulltextPURPOSE: Patients treated with sunitinib show substantial inter-patient variability in drug exposure (~30-40 %), which is largely unexplained.
Gelderblom, H.   +12 more
core   +1 more source

Interpretable Drug–Target Prediction via Geometric Alignment: A Linear Alternative to Deep Architectural Complexity

open access: yesMolecular Informatics, Volume 45, Issue 11, November 2026.
The Multi‐View Linear Manifold (MVLM) aligns frozen chemical and protein language model embeddings in a shared geometric space using two linear projections. Binding is scored by a single dot product. MVLM achieves state‐of‐the‐art drug–target interaction prediction on KIBA, performs competitively on Davis, and recovers kinase phylogenetic structure ...
Aashutosh Ghimire   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy